Ivermectin and Gynecologic Cancer: What are the data?

•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to ef...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Gynecologic oncology reports Ročník 60; s. 101803
Hlavní autori: Mujumdar, Vaidehi, Huang, Marilyn, Smith, Lindsey Chippendale, Musa, Fernanda
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Elsevier Inc 01.08.2025
Elsevier
Predmet:
Anti-helminthic
COVID-19
Gynecologic cancers
Ivermectin
Wonder drug
COVID-19
Gynecologic cancers
Wonder drug
Anti-helminthic
Ivermectin
ISSN:2352-5789, 2352-5789
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2025.101803